CavoGene LifeSciences, a biotechnology company, has appointed Daniel Jorgensen, MD, MPH, MBA as its new chief executive officer, it was reported on Tuesday.

With over 22 years of experience in small and large companies, both public and private, including C-level positions over the past nine years, Dr Jorgensen has accrued comprehensive research, development, and commercialisation experience for small molecules, biologics/vaccines, and devices, across multiple therapeutic areas, particularly infectious diseases, immunology/inflammation, and rare genetic disorders, playing a main role in multiple regulatory approvals.

Dr Jorgensen holds a BS degree from Yale, MD from University of Wisconsin, MPH from University of Washington and MBA from Yale and holds board certifications in Paediatrics, Infectious Diseases, and Preventive Medicine.